Engineered exosomes with KrasG12D specific siRNA in pancreatic cancer: a phase I study with immunological correlates
8.0
来源：
Nature
关键字：
ML brain science
发布时间：
2025-10-01 07:43
摘要：
The Phase I clinical trial of engineered exosomes containing KRASG12D specific siRNA (iExoKrasG12D) in pancreatic cancer patients demonstrated safety and tolerability, with no dose-limiting toxicities observed. Preclinical studies indicated significant anti-tumor efficacy, particularly when combined with immune checkpoint inhibitors. This innovative approach addresses a critical need in treating pancreatic ductal adenocarcinoma, a notoriously lethal cancer, and suggests a promising avenue for future therapies.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
iExoKrasG12D therapy was well-tolerated with no dose-limiting toxicity.
The maximum tolerated dose was not reached even at the highest dose.
Combination therapy with iExoKrasG12D and anti-CTLA-4 antibodies showed robust pre-clinical anti-tumor efficacy.
真实性检查
否
AI评分总结
The Phase I clinical trial of engineered exosomes containing KRASG12D specific siRNA (iExoKrasG12D) in pancreatic cancer patients demonstrated safety and tolerability, with no dose-limiting toxicities observed. Preclinical studies indicated significant anti-tumor efficacy, particularly when combined with immune checkpoint inhibitors. This innovative approach addresses a critical need in treating pancreatic ductal adenocarcinoma, a notoriously lethal cancer, and suggests a promising avenue for future therapies.